Non-communicable diseases such as cancer and cardiovascular disorders kill millions of people each year, with numbers increasing particularly in low- and middle-income countries. The IAEA has ...

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study, in ...

Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...

At Bethel, we believe everyone should have the opportunity to explore their passions, discover their purpose, and fulfill their God-given potential. The BUILD program is a Comprehensive Transition and ...

Build the skills, strategy and credibility to lead AI transformation AI is disrupting every sector, but most professionals lack the clarity and confidence to lead it. The LSE AI Leadership Accelerator ...